Alkem Laboratories Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/sgm6ja3lxmlkfnwai2xf3poz.pdf

Key Takeaways


India Business: The One-Off Decline and Recovery Bet

Dr. Vikas Gupta: "my belief is that it's a one-off. If you will see even the IPM and the anti-infective market for Q4 has degrown at around 2.2% which is a very unusual trend."

US Business: Stabilized Pricing, Supply-Chain Friction

Dr. Vikas Gupta: "We every day read reports in newspapers that US is going through a drug shortage for many products. For that to happen, the products need to be available over there. And I think it's translating even in our numbers where we are seeing the prices getting more or less bottomed out for many products."

Enzene Biosimilars & US CDMO: The Strategic Bet

Dr. Vikas Gupta: "It's to meet up on the CDMO business that we have in the US market. So, there were companies like Wuxi Biologicals who are really catering to this market and their multi-billion dollar business as far as this business was concerned. Now with US facing pressures because of geopolitical reasons, so some of these companies are not doing the kind of business that they were doing and which threw up an opportunity for players like us to consider, entry into the CDMO business as far as U.S. market is concerned."

Margin Drivers and Sustainability

Dr. Vikas Gupta: "I can tell you is that we have one of the largest consumers of PenG and if Pen G prices ease out, we will be happier than anyone else."

New Business Ventures


Guidance & Commitments

CommitmentSpecificsTimeline
Revenue growth~10%, in line with market growth, largely volume-led from domestic businessFY25
Domestic business growth10% growthFY25
US new launch contribution6–7 launches, one relaunch, contributing ~7%–8% growthFY25
EBITDA marginMore or less in line with FY24's 17.7%, with maybe 20–30 bps improvementFY25
R&D spend4.5% to 5% of sales, including biosimilar clinical trialsFY25
CAPEX₹600 to ₹700 croresFY25
Tax rate13% to 15% for next two years; rising to ~25% in FY27 when second tax benefit endsFY25–FY27
Enzene US plant operationalPlant ready in H2; revenue from Q4 FY25 or Q1 FY26FY25–FY26
Enzene US plant opex₹30–40 crores in FY25, rising to ₹120–130 crores in FY26FY25–FY26
US supply-chain penaltiesExpect to bring down service-level penaltiesFY25
Chronic portfolio contributionExpected to cross 20%Near-to-mid term
Trade generic contributionRemain in 20%–22% rangeGoing forward
Biosimilar launchesNo launches in FY25; maybe some next yearFY26

Key Metrics

MetricQ4 FY24
Revenue from operationsNot explicitly stated for Q4; FY24 international business crossed ₹4,000 cr
EBITDA margin13.7%, improved 150 bps YoY from 12.2%
Net profit after tax₹294 cr; adjusted PAT growth roughly 54% YoY excluding ₹120 cr deferred tax derecognition in Q4 FY23
Net profit before tax (FY24)>₹2,000 cr, first time crossing this threshold
Gross marginManagement expects to maintain within current range; Q4 saw significant enhancements backed by lower raw material costs
R&D spend4.1% of revenue in FY24; guided to 4.5%–5.0% going forward
Cash generated (FY24)~₹1,400 cr
Net cash position~₹3,550 cr
CAPEX guidance (FY25)₹600–700 cr, including ~₹400 cr for new US facility and ₹80–100 cr maintenance CAPEX
India business growth guidance (FY25)~10%, in line with IPM or plus one cent; 3% from price, 1–2% from new launches, balance volume-led
US business quarterly sales$74–$75 million, down from $80 million+ in prior quarters due to seasonality and supply issues
US business price erosionStabilized at low single digit
US business new launches (FY25)6–7 launches expected, contributing 7–8% growth
ANDA approvals in Q42
Trade generic contribution to domestic business~20%, within 20–21% range; expected to remain 20–22% going forward
Chronic portfolio contribution17–18% of domestic business; expected to cross 20% in near-to-mid-term
Biosimilar portfolio (domestic)7 products launched; contributes ~5% of overall domestic business
Field force headcount~12,000
Service level penalties (US supply chain)₹30 cr in Q4; ₹120 cr for full year
Tax rate guidance13–15% for next two years; increasing to ~25% from FY27
Enzene US plant operational expenses (FY25)₹30–40 cr; annualized ~₹120–130 cr in FY26
Anti-infective therapy growth expectation (FY25)7–8%
IPM anti-infective market growth (Q4 FY24)Degrown ~2.2%